Herceptin news from FiercePharma
NewsASCO already churning out news
Today marks the start of the annual American Society of Clinical Oncology meeting, always a big news generator in the pharma biz. We'll let our sister pub FierceBiotech keep you up to date on the... Read more...
Pro/Con on FDA off-label proposal
One of the things media love to do is get two people to go head-to-head on an issue. Today's topic: Allowing drugmakers to distribute peer-reviewed journal articles in support of off-label uses for... Read more...
Pfizer, Roche suffer as big drugs falter
Today's earnings roundup is a snapshot of pharma's challenges--generic... Read more...
High-priced meds spur dosing debate
What's a drug worth? In the case of Cerezyme, a remedy for a rare inherited enzyme deficiency known as Gaucher disease, the answer is $300,000 a year. But experts are questioning whether lower doses... Read more...
SPOTLIGHT: NIH starts Tykerb vs. Herceptin bout
It's a head-to-head matchup. The National Institutes of Health has launched an 8,000-patient trial pitting GlaxoSmithKline's Tykerb against Genentech's Herceptin in aggressive breast cancer.... Read more...
SPOTLIGHT: NZ Activists challenge Herceptin denial
Breast Cancer survivors in New Zealand won a small victory in their challenge to the government's decision not to fund a full course of Herceptin treatment; the women have won the right to see... Read more...
Roche sales surpass Novartis'
Eat dust, Novartis. Roche just posted sales of $42.2 billion, $2.4 billion more than its Swiss rival's $39.8 billion. Strong sales of its cancer drugs helped boost profits by 25 percent to $10.48... Read more...
Breast cancer diagnostics often wrong
So far, personalized medicine isn't perfectly personalized. New data shows that diagnostic tests to determine whether women should take certain breast cancer drugs have a failure rate of up to... Read more...
Expensive Herceptin draws fire in UK
Roche's drug Herceptin has become a lightning rod for debate over cancer treatment in England. Radiotherapists--including the specialty's chief at the National Health Service--are saying that cancer... Read more...
Genentech, Roche rise on cancer sales
Here's Exhibit Z in the long list of reasons why Big Pharma wants to make deals with biotech--and why speculation about Biogen and Genzyme... Read more...
| Press ReleasesPRESS RELEASE: Herceptin eradicates tumours and may reduce the need for mastectomies in women Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer – one of the most aggressive and fastest growing forms of the disease Read more >> |
Get more Herceptin coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
